Immunis Launches Preclinical Studies for Canine Muscle Atrophy Treatment

Immunis, Inc., a clinical-stage biotechnology company focused on developing innovative secretomes for age-related diseases and immune dysfunction, has launched non-terminal safety studies for canine muscle atrophy in collaboration with VetBio Partners, LLC. This follows the successful preclinical results of Immunis’…

Read MoreImmunis Launches Preclinical Studies for Canine Muscle Atrophy Treatment

Inquis Medical Secures $40M in Series B Funding to Advance Aventus Thrombectomy System

Inquis Medical, an innovator in advanced thrombectomy systems, today announced the successful closure of its oversubscribed $40 million Series B financing round. The round was led by Marshall Wace, a globally renowned investment firm, with strong support from existing investors…

Read MoreInquis Medical Secures $40M in Series B Funding to Advance Aventus Thrombectomy System
Bayer

Biomodal to Present 6-Base Genome Data on Early Colorectal Cancer Detection at ASHG 2024

Biomodal, an omics-based life sciences technology and analytics company, announced today that it will present new data showcasing the effectiveness of its duet multiomics solution, evoC, in the early detection of diseases. This solution differentiates between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine…

Read MoreBiomodal to Present 6-Base Genome Data on Early Colorectal Cancer Detection at ASHG 2024

Centene’s Buckeye Health Plan Wins Contract for Dual Eligible Medicare and Medicaid Members in Ohio”

Centene Corporation (NYSE: CNC), a prominent healthcare enterprise dedicated to improving lives, announced that its subsidiary, Buckeye Health Plan, has been selected by the Ohio Department of Medicaid (ODM) to continue offering services for dually eligible individuals through a Fully…

Read MoreCentene’s Buckeye Health Plan Wins Contract for Dual Eligible Medicare and Medicaid Members in Ohio”